Sarepta Subsidiary Files Form 144 to Sell 9.27M ARWR Shares

Rhea-AI Filing Summary

Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., filed a Form 144 notice indicating a proposed sale of 9,265,312 shares of common stock of the issuer through Jefferies LLC on Nasdaq. The filing reports an aggregate market value of $185,213,586.88 and lists total shares outstanding as 138,257,550. The approximate date of sale is 08/13/2025.

The filing states these securities were acquired in a private placement from the issuer on 02/07/2025 by Sarepta Therapeutics Investments, Inc., with 11,926,301 shares acquired and payment made in cash on that date. The notice includes the standard representation that the person for whose account the securities are to be sold does not know of any undisclosed material adverse information.

Positive

• Brokered sale through Jefferies LLC on Nasdaq indicates the transaction is being facilitated by a registered broker.
• Securities were acquired in a private placement and paid in cash on 02/07/2025, with acquisition details disclosed in the filing.

Negative

• Proposed sale of 9,265,312 shares with an aggregate market value of $185,213,586.88 is sizable relative to the companys reported shares outstanding (138,257,550).
• 11,926,301 shares were acquired in the private placement on 02/07/2025, indicating the filing relates to a substantial block of recently issued securities.

Insights

Securities Analyst

TL;DR: Large Rule 144 notice filed for 9.27M ARWR shares (about $185.2M), to be sold via Jefferies on Nasdaq on 08/13/2025.

The Form 144 documents a proposed sale of 9,265,312 shares with an aggregate market value of $185,213,586.88, to be executed through Jefferies LLC on Nasdaq. The securities were acquired in a private placement on 02/07/2025 and paid for in cash. This filing provides the required regulatory disclosure under Rule 144 and notifies the market of an intended secondary sale. The notice also confirms the filer represents no undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Disclosure shows compliance with Rule 144 procedures for a sizeable sale by a Sarepta subsidiary; broker and acquisition details are documented.

The filing identifies Jefferies LLC as the broker and records the acquisition source as the issuer via a private placement on 02/07/2025, with 11,926,301 shares acquired by Sarepta Therapeutics Investments, Inc. The Form 144 includes the customary attestation regarding material adverse information, indicating the seller is meeting Form 144 disclosure requirements for an intended sale on 08/13/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common stock, par value $0.001 per share	Jefferies LLC 520 Madison Avenue New York NY 10022	9265312	185213586.88	138257550	08/13/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common stock, par value $0.001 per share	02/07/2025	The common stock reported herein was acquired by Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., in a private placement transaction.	Issuer			11926301	02/07/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ARWR's Form 144 notify investors about?

The Form 144 notifies investors that 9,265,312 shares of common stock are proposed to be sold through Jefferies LLC on Nasdaq, with an approximate sale date of 08/13/2025.

Who is the broker handling the proposed sale of ARWR shares?

The filing lists Jefferies LLC at 520 Madison Avenue, New York, NY as the broker.

What is the aggregate market value of the shares listed in the Form 144?

The aggregate market value reported in the filing is $185,213,586.88.

How many ARWR shares were outstanding according to the filing?

The filing reports 138,257,550 shares outstanding.

Who acquired the securities being sold and when were they acquired?

The securities were acquired by Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc. in a private placement from the issuer on 02/07/2025; the filing shows 11,926,301 shares were acquired and paid for in cash.

Does the filer attest to having any undisclosed material adverse information?

By signing the notice the filer represents they do not know any material adverse information